Inhibition of fatty acid synthase expression by 1α,25-dihydroxyvitamin D3 in prostate cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 85, Issue 1, 2003, Pages 1-8

  Qiao, Shengjun ^a   Pennanen, Pasi ^a   Nazarova, Nadja ^a   Lou, Yan Ru ^a   Tuohimaa, Pentti ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

1 ,25 Dihydroxyvitamin D3; Antiandrogen; Cell proliferation; Fatty acid synthase; Gene regulation

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CALCITRIOL; CERULENIN; COMPLEMENTARY DNA; CYCLOHEXIMIDE; FATTY ACID SYNTHASE; PROTEIN; PROTEIN SYNTHESIS INHIBITOR; VITAMIN D;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE PROBE; GENE TARGETING; GENETIC CODE; GENETIC REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM;

EID: 0037783278     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00142-0     Document Type: Article

References (31)

1. Tuohimaa P., Lyakhovich A., Aksenov N., Pennanen P., Syvälä H., Lou Y.-R., Ahonen M., Hasan T., Pasanen P., Bläuer M., Manninen T., Miettinen S., Vilja P., Ylikomi T. Vitamin D and prostate cancer. J. Steroid Biochem. Mol. Biol. 76:2001;125-134.
2. Ylikomi T., Laaksi I., Lou Y.-R., Martikainen P., Miettinen S., Pennanen P., Purmonen S., Syvälä H., Vienonen A., Tuohimaa P. Antiproliferative action of vitamin D. Vitam. Horm. 64:2002;357-406.
3. Ahonen M.H., Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 11:2000;847-852.
4. Huhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., Pasternack G.R. Fatty acid synthase: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. U.S.A. 91:1994;6379-6383.
5. Gabrielson E.W., Pinn M.L., Testa J.R., Kuhajda F.P. Increased fatty acid synthase is a therapeutic target in Mesothelioma. Clin. Cancer Res. 7:2001;153-157.
6. Pizer E.S., Pflug B.R., Bova G.S., Hen W.F., Udan M.S., Nelson J.B. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 47:2001;102-110.
7. Kalkhoven E., Kwakkenbos-Isbrucker L., de Laat S.W., van der Saag P.T., van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone and estrogen receptor. Mol. Cell Endocrinol. 102:1994;45-52.
8. Chalbos D., Joyeux C., Galtier F., Escot C., Chambon M., Maudelonde T., Rochefort H. Regulation of fatty acid synthetase by progesterone in normal and tumoral human mammary glands. Rev. Esp. Fisiol. 46:1990;43-46.
9. Escot C., Joyeux C., Mathieu M., Maudelonde T., Pages A., Rochefort H., Chalbos D. Regulation of fatty acid synthetase ribonucleic acid in the human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 70:1990;1319-1324.
10. Kuhajda F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 16:2000;202-208.
11. Pizer E.S., Kurman R.J., Pasternack G.R., Kuhajda F.P. Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium. Int. J. Gynecol. Pathol. 16:1997;45-51.
12. Pizer E.S., Lax S.F., Kuhajda F.P., Pasternack G.R., Kurman R.J. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer. 83:1998;528-537.
13. Gansler T.S., Hardman W. III, Hunt D.A., Schaffel S., Henniger R.A. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol. 28:1997;686-692.
14. Shurbaji M.S., Kuhajda F.P., Pasternack G.R., Thurmond T.S. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. Am. J. Clin. Pathol. 97:1992;686-691.
15. Jensen V., Ladekari M., Holm-Nielsen P., Flemming B.S., Flemming M. Prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node negative breast cancer. J. Pathol. 176:1995;343-352.
16. Epstein J.I., Carmichael M., Partin A.W. OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology. 45:1995;81-86.
17. Alo' P.L., Visca P., Marci A., Mangoni A., Botti C., Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 77:1996;474-482.
18. Rashid A., Pizer E.S., Moga M., Milgraum L.Z., Zahurak M., Pasternack G.R., Kuhajda F.P., Hamilton S.R. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am. J. Pathol. 150:1997;201-208.
19. Pizer E.S., Lax S.F., Kuhajda F.P., Pasternack G.R., J Kurman R. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer. 83:1998;528-537.
20. Pizer E.S., Chrest F.J., Digiuseppe J.A., Han W.F. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 58:1998;4611-4615.
21. Swinnen J.S., Vanderhoydonc F., Elgemal A.A., Eelen M., Vercaeren I., Joniau S., Van Poppel H., Baert L., Goossens K., Heyns W., Verhoeven G. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int. J. Cancer. 88:2000;176-179.
22. Swinnen J.V., Roskams T., Joniau S., Van Poppel H., Oyen R., Baert L., Heyns W., Verhhoven G. Overexpression of fatty acid synthase in an early and common event in the development of prostate cancer. Int. J. Cancer. 98:2002;19-22.
23. Furuya Y., Akimoto S., Yasada K., Ito H., Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthase Anticancer Res. 17:1997;4589-4593.
24. Pizer E.S., Jackisch C., Wood F.D., Pasternack G.R., Davidson N.E., Kuhajda F.P. Inhibition of fatty acid synthase induces programmed cell death in human breast cancer cells. Cancer Res. 56:1996;2745-2747.
25. McLeod H.L., Cassidy J., Powrie R.H., Priest D.G., Zorbas M.A., Synold T.W., Shibata S., Spicer D., Bissett D., Pithavala Y.K., Collier M.A., Paradiso L.J., Roberts J.D. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin. Cancer Res. 6:2000;2677-2684.
26. Jack G.W., Wiblin C.N., McMahon P.C. The effect of histidine ammonia-lyase on some murine tumours. Leuk. Res. 7:1983;421-429.
27. 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanism. Endocrinology. 141:2000;2548-2556.
28. Veldscholte J., Berrevoets C.A., Ris-Stalpers C., Kuiper G.G.J.M., Jenster G., Trapman J., Brinkmann A.O., Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41:1992;665-669.
29. Swinnen J.V., Esquenet M., Goossens K., Heyns W., Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 57:1997;1086-1090.
30. 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology. 140:1999;1205-1212.
31. Pizer E.S., Wood F.D., Pasternack G.R., Kuhajda F.P. Fatty acid synthase (FAS): a target for cytotoxic antimetabolities in HL60 promyelocytic leukemia cells. Cancer Res. 56:1996;745-751.